The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: In-hospital-data from the atrial fibrillation undergoing coronary artery stenting study

Catheterization and Cardiovascular Interventions

Volumn 82, Issue 7, 2013, Pages

  Schlitt, Axel ^a,b   Rubboli, Andrea ^c   Lip, Gregory Y H ^d   Lahtela, Heli ^e   Valencia, Josè ^f   Karjalainen, Pasi P ^g   Weber, Michael ^h   Laine, Mika ⁱ   Kirchhof, Paulus ^d,j   Niemelä, Matti ^k   Vikman, Saila ^l   Buerke, Michael ^a   Airaksinen, K E Juhani ^e  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Department of Cardiology Paracelsus Harz Clinic   (Germany)

^c MAGGIORE HOSPITAL   (Italy)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e UNIVERSITY OF TURKU   (Finland)

^f UNIVERSITY OF ALICANTE   (Spain)

^g SATAKUNTA CENTRAL HOSPITAL   (Finland)

^h KERCKHOFF HEART CENTER   (Germany)

ⁱ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^j UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^k OULU UNIVERSITY HOSPITAL   (Finland)

^l TAMPERE UNIVERSITY HOSPITAL   (Finland)

more..

Author keywords

antiplatelets; atrial fibrillation; coronary heart disease; oral anticoagulation

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; ADVERSE OUTCOME; AGED; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CONTROLLED STUDY; CORONARY STENT; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE CARE; PROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; THROMBOEMBOLISM; THROMBOSIS;

ANTIPLATELETS; ATRIAL FIBRILLATION; CORONARY HEART DISEASE; ORAL ANTICOAGULATION;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; EUROPE; FEMALE; GUIDELINE ADHERENCE; HEMORRHAGE; HOSPITAL MORTALITY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; SEX FACTORS; STENTS; STROKE; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME;

EID: 84888135235     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.25064     Document Type: Article

References (14)

1. Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T, Kirchhof P, Marín F,; Consensus Document of European Society of Cardiology Working Group on Thrombosis. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: Executive summary-a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2010; 31: 1311-1318.
2. Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ,. Consensus document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106: 522-584.
3. Rubboli A, Dewilde W, Huber K, Eeckhout E, Herzfeld I, Valencia J, Windecker S, Airaksinen KE, Lip GY,. The management of patients on oral anticoagulation undergoing coronary stent implantation: A survey among interventional cardiologists from eight European countries. J Interv Cardiol 2012; 25: 163-169.
4. Karjalainen PP, Vikman S, Niemelä M, Porela P, Ylitalo A, Vaittinen MA, Puurunen M, Airaksinen TJ, Nyman K, Vahlberg T, Airaksinen KE,. Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. Eur Heart J 2008; 29: 1001-1010.
5. Lahtela H, Karjalainen PP, Niemelä M, Vikman S, Kervinen K, Ylitalo A, Puurunen M, Porela P, Nyman K, Hinkka-Yli-Salomäki S, Airaksinen KE,. Are glycoprotein inhibitors safe during percutaneous coronary intervention in patients on chronic warfarin treatment? Thromb Haemost 2009; 102: 1227-1233.
6. Rubboli A, Colletta M, Valencia J, Capecchi A, Franco N, Zanolla L, La Vecchia L, Piovaccari G, Di Pasquale G,; WARfarin and Coronary STENTing (WAR-STENT) Study Group. Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting. J Interv Cardiol 2009; 22: 390-397.
7. Gilard M, Blanchard D, Helft G, Carrier D, Eltchaninoff H, Belle L, Finet G, Le Breton H, Boschat J,; STENTICO Investigators. Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTIng and oral antiCOagulants [STENTICO]). Am J Cardiol 2009; 104: 338-342.
8. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH,. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Eur Heart J 2010; 31: 2369-2429.
9. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML,. Thrombolysis in myocardial infarction (timi) trial-Phase i: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1-11.
10. Rubboli A, Milandri M, Castelvetri C, Cosmi B,. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. Cardiology 2005; 104: 101-106.
11. Dewilde W, Berg JT,. Design and rationale of the WOEST trial: What is the optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST). Am Heart J 2009; 158: 713-718.
12. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L,; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
13. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM,; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
14. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L,; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.